DVAX Projected Dividend Yield
Dynavax Technologies Corp ( NASDAQ : DVAX )Dynavax Technologies is a commercial stage biopharmaceutical company engaged in developing and commercializing vaccines. Co.'s primary marketed product, Hepatitis B Vaccine (Recombinant), Adjuvanted (HEPLISAV-B), is approved in the U.S. and European Union for prevention of infection caused by known subtypes of hepatitis B virus in adults age 18 years and older. Co. also manufactures and sells CpG oligonucleotide (CpG) 1018 adjuvant, the vaccine adjuvant used in HEPLISAV-B. Co. developed CpG 1018 adjuvant to provide an increased vaccine immune response. 20 YEAR PERFORMANCE RESULTS |
DVAX Dividend History Detail DVAX Dividend News DVAX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |